An observational study in Myelodysplastic Syndromes, sponsored by Bristol-Myers Squibb. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by Bristol-Myers Squibb · Observational
The purpose of this study is to evaluate the treatment patterns and clinical outcomes in adults with lower-risk MDS (LR-MDS) who were erythropoiesis-stimulating agents (ESA)-naïve and received luspatercept treatment in China
2,124 studies on the registry are indexed under Myelodysplastic Syndromes; 320 are open to participants now.
This study's enrollment of 88 is below the median of 146 across 215 observational studies indexed under Myelodysplastic Syndromes.
Browse Myelodysplastic Syndromes studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population will comprise of individuals ≥18 years of age diagnosed with Lower-Risk Myelodysplastic Syndromes (LR-MDS) were erythropoiesis-stimulating agents (ESA)-naïve and received luspatercept treatment in China
Exclusion Criteria:
Drug: Luspatercept
According to the product label
Participant red blood cell transfusion independence
Time frame: Up to 12-weeks
Participants mean hemoglobin (Hb) increase ≥1.5 g/dL
Time frame: Up to 12-weeks
Participant transfusion independence and increase in hemoglobin (Hb)
Time frame: Up to 48 weeks
Duration of luspatercept monotherapy treatment
Time frame: Up to 48 weeks
Health Care Resource Utilization (HCRU)
Time frame: Up to 48 weeks
Plan to share: No
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb